(Q34164670)

31 July 2017

1 reference

title

Design and application of diabodies, triabodies and tetrabodies for cancer targeting (English)

1 reference

31 July 2017

Todorovska A

1

1 reference

31 July 2017

Roovers RC

2

1 reference

31 July 2017

Dolezal O

3

1 reference

31 July 2017

Kortt AA

4

1 reference

31 July 2017

Hoogenboom HR

5

1 reference

31 July 2017

Hudson PJ

6

1 reference

31 July 2017

1 February 2001

1 reference

Journal of Immunological Methods

31 July 2017

1 reference

31 July 2017

248

1 reference

31 July 2017

1-2

1 reference

31 July 2017

47-66

1 reference

Generating improved single-chain Fv molecules for tumor targeting

31 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Radioimmunotherapy of colorectal carcinoma xenografts in nude mice with yttrium-90 A33 IgG and Tri-Fab (TFM)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Factors Influencing the Dimer to Monomer Transition of an Antibody Single-Chain Fv Fragment†

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Design and expression of a stable bispecific scFv dimer with affinity for both glycophorin and N9 neuraminidase.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

scFv multimers of the anti-neuraminidase antibody NC10: length of the linker between VH and VL domains dictates precisely the transition between diabodies and triabodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

The biology of the 17-1A antigen (Ep-CAM)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Binding characteristics and tumor targeting of a covalently linked divalent CC49 single-chain antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Single-chain antigen-binding proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Stabilization of a recombinant Fv fragment by base-loop interconnection and V(H)-V(L) permutation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Purification of bacterially expressed single chain Fv antibodies for clinical applications using metal chelate chromatography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab' fragments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Construction of recombinant extended single-chain antibody peptide conjugates for use in the diagnosis of HIV-1 and HIV-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Monoclonal antibodies for treating cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

ScFv multimers of the anti-neuraminidase antibody NC10: shortening of the linker in single-chain Fv fragment assembled in V(L) to V(H) orientation drives the formation of dimers, trimers, tetramers and higher molecular mass multimers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Tumor-specific T-bodies: towards clinical application

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Improved tumour targeting by disulphide stabilized diabodies expressed in Pichia pastoris

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Clinical effects of monoclonal antibodies (MAb 17-1A) in patients with metastatic colorectal carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

The epithelial cell surface antigen 17-1A, a target for antibody-mediated tumor therapy: its biochemical nature, tissue distribution and recognition by different monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Construction and characterization of a bispecific diabody for retargeting T cells to human carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

"Diabodies": small bivalent and bispecific antibody fragments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Retargeting serum immunoglobulin with bispecific diabodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Recombinant antibody fragments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Recombinant antibody constructs in cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Recombinant antibodies: a novel approach to cancer diagnosis and therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

High avidity scFv multimers; diabodies and triabodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Triabodies: single chain Fv fragments without a linker form trivalent trimers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

High level production of soluble single chain antibodies in small-scale Escherichia coli cultures.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Bispecific CD3 x CD19 diabody for T cell-mediated lysis of malignant human B cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Intracellular and cell surface displayed single-chain diabodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Complement recruitment using bispecific diabodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Enzyme immunoassays using bispecific diabodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Recombinant anti-sialidase single-chain variable fragment antibody. Characterization, formation of dimer and higher-molecular-mass multimers and the solution of the crystal structure of the single-chain variable fragment/sialidase complex.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Single-chain Fv fragments of anti-neuraminidase antibody NC10 containing five- and ten-residue linkers form dimers and with zero-residue linker a trimer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Specific targeting of cytokine-secreting cells: a bispecific diabody recognizing human interleukin-6 and CD3 induces T cell-mediated killing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Orientation of antigen binding sites in dimeric and trimeric single chain Fv antibody fragments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Di-, tri- and tetrameric single chain Fv antibody fragments against human CD19: effect of valency on cell binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Epithelial cell adhesion molecule (Ep-CAM) modulates cell-cell interactions mediated by classic cadherins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

The structure of a complex between the NC10 antibody and influenza virus neuraminidase and comparison with the overlapping binding site of the NC41 antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Three-dimensional structures of single-chain Fv-neuraminidase complexes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

CD3X anti-nitrophenyl bispecific diabodies: universal immunotherapeutic tools for retargeting T cells to tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Engineering disulfide-linked single-chain Fv dimers [(sFv')2] with improved solution and targeting properties: anti-digoxin 26-10 (sFv')2 and anti-c-erbB-2 741F8 (sFv')2 made by protein folding and bonded through C-terminal cysteinyl peptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Phage diabody repertoires for selection of large numbers of bispecific antibody fragments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Model and Simulation of Multivalent Binding to Fixed Ligands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

A dimeric bispecific miniantibody combines two specificities with avidity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

High-affinity antigen binding by chelating recombinant antibodies (CRAbs).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Tetravalent miniantibodies with high avidity assembling in Escherichia coli.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Anatomy of the antibody molecule

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Charge-modified single chain antibody constructs of monoclonal antibody CC49: generation, characterization, pharmacokinetics, and biodistribution analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Comparative radioimmunotherapy using intact or F(ab')2 fragments of 131I anti-CEA antibody in a colonic xenograft model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

The 2.0-A resolution crystal structure of a trimeric antibody fragment with noncognate VH-VL domain pairs shows a rearrangement of VH CDR3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Crystal structure of a diabody, a bivalent antibody fragment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

New protein engineering approaches to multivalent and bispecific antibody fragments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Synthesis of high avidity antibody fragments (scFv multimers) for cancer imaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Tumor targeting with newly designed biparatopic antibodies directed against two different epitopes of the carcinoembryonic antigen (CEA).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

High-affinity recombinant phage antibodies to the pan-carcinoma marker epithelial glycoprotein-2 for tumour targeting.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Bispecific antibodies in cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Bivalent binding of a neutralising antibody to a calicivirus involves the torsional flexibility of the antibody hinge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Importance of the linker in expression of single-chain Fv antibody fragments: optimisation of peptide sequence using phage display technology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Antibody engineering: comparison of bacterial, yeast, insect and mammalian expression systems.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

The 'adenobody' approach to viral targeting: specific and enhanced adenoviral gene delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Multivalent Fvs: characterization of single-chain Fv oligomers and preparation of a bispecific Fv

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Mutual Stabilization of VLand VHin Single-Chain Antibody Fragments, Investigated with Mutants Engineered for Stability†

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Structure of a single-chain antibody variable domain (Fv) fragment complexed with a carbohydrate antigen at 1.7-A resolution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

Remodeling domain interfaces to enhance heterodimer formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

The development of monoclonal antibodies for the therapy of cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2800%2900342-2

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0022-1759(00)00342-2

1 reference

31 July 2017

1 reference